<table>
<thead>
<tr>
<th><strong>Drug/Drug Class:</strong></th>
<th>Duchenne Muscular Dystrophy (DMD) Clinical Edit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Implementation Date:</strong></td>
<td>February 6, 2020</td>
</tr>
<tr>
<td><strong>Revised Date:</strong></td>
<td>August 17, 2020</td>
</tr>
<tr>
<td><strong>Prepared for:</strong></td>
<td>MO HealthNet</td>
</tr>
<tr>
<td><strong>Prepared by:</strong></td>
<td>MO HealthNet/Conduent</td>
</tr>
</tbody>
</table>
| **Criteria Status:** | ☐ Existing Criteria  
☐ Revision of Existing Criteria  
☒ New Criteria |

**Executive Summary**

**Purpose:** Ensure appropriate utilization and control of agents for Duchenne Muscular Dystrophy (DMD)

**Why Issue Selected:** Duchenne muscular dystrophy (DMD) is a fatal, X-linked recessive neuromuscular disorder caused by mutations in the dystrophin gene; these mutations lead to absent or insufficient functional dystrophin, a cytoskeletal protein which enables the strength, stability, and functionality of myofibers. The absence or lack of dystrophin results in muscle degradation and scarring, leading to muscle weakness, associated motor delays, loss of ambulation, respiratory impairment, and cardiomyopathy. DMD is the most common pediatric muscular dystrophy, with a prevalence of 1 in 3,500 to 5,000 live male births (about 400-600 boys per year in the US); rarely females who are carriers may be symptomatic. Although the clinical course may vary, death usually occurs as a result of cardiac or respiratory compromise.

Emflaza® (deflazacort), an oxazoline derivative of prednisone, was FDA approved in February 2017, and is currently indicated to treat DMD in patients 2 years of age and older. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system. Prednisone, although it is not FDA approved for the indication, is also frequently prescribed for DMD. Long term steroid therapy has shown benefits in treating DMD, including loss of ambulation at a later age, preserved upper limb and respiratory function, and avoidance of scoliosis surgery. The benefit-to-risk ratio of Emflaza compared to prednisone is being further studied at this time. The Duchenne Muscular Dystrophy Care Considerations committee noted in 2018 that compared to prednisone, Emflaza may increase the risk of growth delay and cataracts and lower the risk for weight gain and behavioral problems.

Exondys 51® (eteplirsen) was FDA approved in September 2016, via an accelerated pathway, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping (approximately 13% of the DMD population). Vyondys 53™ (golodirsen) was FDA approved in December 2019, for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping (approximately 8% of the DMD population). Both Exondys 51 and Vyondys 53 are manufactured by Sarepta Therapeutics, who also have an exon 45 skipping therapy currently in Phase III trials. Both Exondys 51 and Vyondys 53 are delivered by a once weekly IV infusion. Although patients receiving either Exondys 51 or Vyondys 53 had an increase in dystrophin in skeletal muscle, a clinical
benefit of this increase has not been established; continued FDA approval may be contingent upon verification of a clinical benefit in a confirmatory trial. Exondys 51 was to have post-marketing results finalized by 2021, but the manufacturer has revealed delays in initiation of the trial and now expects results to be finalized by 2024. The post-marketing confirmatory trial for Vyondys 53 is expected to be completed by 2024 as well.

### Program-Specific Information:

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dose / Form</th>
<th>Units</th>
<th>Cost per Unit MAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emflaza® 22.75mg/mL susp</td>
<td>0</td>
<td>-</td>
<td>$278.49 per ml MAC</td>
</tr>
<tr>
<td>Emflaza® 6mg tablet</td>
<td>0</td>
<td>-</td>
<td>$54.95 per tab MAC</td>
</tr>
<tr>
<td>Emflaza® 18mg tablet</td>
<td>0</td>
<td>-</td>
<td>$164.86 per tab MAC</td>
</tr>
<tr>
<td>Emflaza® 30mg tablet</td>
<td>32</td>
<td>$170,164.32</td>
<td>$274.79 per tab MAC</td>
</tr>
<tr>
<td>Emflaza® 36mg tablet</td>
<td>19</td>
<td>$159,681.33</td>
<td>$306.21 per tab MAC</td>
</tr>
<tr>
<td>Exondys 51® 100mg/2ml vial</td>
<td>102</td>
<td>$708,531.67</td>
<td>$808.00 per ml MAC</td>
</tr>
<tr>
<td>Exondys 51® 500mg/10ml vial</td>
<td>152</td>
<td>$9,351,819.15</td>
<td>$808.00 per ml MAC</td>
</tr>
<tr>
<td>Vyondys 53™ 100mg/2ml vial</td>
<td>0</td>
<td>-</td>
<td>$808.00 per ml MAC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dose / Form</th>
<th>Units</th>
<th>Cost per Month MAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emflaza® susp (dose = 22.5mg/day)</td>
<td>22.75mg daily (2 bottles of 13 ml)</td>
<td>-</td>
<td>$7,240.74 per 26 day supply</td>
</tr>
<tr>
<td>Emflaza® tablets (dose = 22.5mg/day)</td>
<td>18mg tab daily</td>
<td>-</td>
<td>$4,945.80 per 30 day supply</td>
</tr>
<tr>
<td></td>
<td>24mg daily (18mg tab + 6mg tab)</td>
<td>-</td>
<td>$6,594.30 per 30 day supply</td>
</tr>
<tr>
<td>Exondys 51®</td>
<td>750mg once weekly (3 of 2ml vials + 10ml vial)</td>
<td>-</td>
<td>$51,712.00 per 28 day supply</td>
</tr>
<tr>
<td>Vyondys 53™</td>
<td>750mg once weekly (8 of 2ml vials)</td>
<td>-</td>
<td>$51,712.00 per 28 day supply</td>
</tr>
</tbody>
</table>

**Type of Criteria:**
- ☐ Increased risk of ADE
- ☒ Preferred Drug List
- ☒ Appropriate Indications
- ☒ Clinical Edit

**Data Sources:**
- ☐ Only Administrative Databases
- ☒ Databases + Prescriber-Supplied

### Setting & Population

- Drug class for review: Agents for the treatment of Duchenne Muscular Dystrophy (DMD)
- Age range: All appropriate MO HealthNet participants aged 2 years and older

### Approval Criteria

- Documented diagnosis of Duchenne Muscular Dystrophy (DMD) confirmed by:
  - genetic testing for dystrophin gene deletion or duplication **OR**
  - genetic sequencing screening for mutations attributed to DMD **OR**
  - positive muscle biopsy showing absence of dystrophin protein **AND**
- Prescribed by or in consultation with a neurologist or other appropriate specialist **AND**
• Documentation of baseline clinical criteria (ex: BMI, weight, ambulatory status, 6-minute walk test (6MWT), North Star Ambulatory Assessment (NSAA), Brooke Upper Extremity Function Scale, Forced vital Capacity (FVC), GFR, ejection fraction) AND

• For Emflaza:
  o Age ≥ 2 years or older AND
  o Dosed at 0.9mg/kg/day, rounding up to the nearest possible dose AND
  o Documentation of adequate trial and therapy failure, intolerance, or significant weight gain while on prednisone at a therapeutic dose (at least 0.75mg/kg/day or 10mg/kg/weekend)
    ▪ Adequate trial defined as ≥ 6 months of prednisone therapy
    ▪ Intolerance defined as Cushingoid appearance, central (truncal) obesity, diabetes and/or hypertension that is difficult to manage, or behavioral adverse effect
    ▪ Significant weight gain defined as 1 standard deviation above baseline percentile rank weight for height OR ≥ 10% body weight gain over a 6 month period
  o Approval for 6 months, renewal requests must provide documentation of clinical benefit
    ▪ Improvement or stabilization of motor, pulmonary, or cardiac function from baseline (ex: 6MWT, NSAA, Brooke Upper Extremity Scale, FVC, ejection fraction) AND
    ▪ Documentation that adverse events associated with prednisone therapy were resolved through treatment with Emflaza

• For Exondys 51:
  o Age ≥ 4 years and ≤ 19 years AND
  o Genetic testing to confirm pathogenic variant of DMD gene amenable to exon 51 skipping AND
  o Dosed at 30mg/kg once weekly AND
  o Documentation of concurrent prednisone or deflazacort therapy, defined as 6 months in the past 9 months
  o Approval for 6 months, renewal requests must provide documentation of clinical benefit
    ▪ Improvement or stabilization of motor, pulmonary, or cardiac function from baseline (ex: 6MWT, NSAA, Brooke Upper Extremity Scale, FVC, ejection fraction) AND
    ▪ Participant retains meaningful voluntary motor function (ex: participant is able to speak, manipulate objects using upper extremities, ambulate)

• For Vyondys 53:
  o Age ≥ 6 years and ≤ 15 years AND
  o Genetic testing to confirm pathogenic variant of DMD gene amenable to exon 53 skipping AND
  o Dosed at 30mg/kg once weekly AND
  o Documentation of concurrent prednisone or deflazacort therapy, defined as 6 months in the past 9 months
  o Approval for 6 months, renewal requests must provide documentation of clinical benefit
    ▪ Improvement or stabilization of motor, pulmonary, or cardiac function from baseline (ex: 6MWT, NSAA, Brooke Upper Extremity Scale, FVC, ejection fraction) AND
    ▪ Participant retains meaningful voluntary motor function (ex: participant is able to speak, manipulate objects using upper extremities, ambulate)
    ▪ Documentation of monthly monitoring for proteinuria < 2+ AND
    ▪ Documentation of monitoring for elevated serum cystatin C every three months

Denial Criteria

• Therapy will be denied if no approval criteria are met

Required Documentation

Laboratory Results: X
MedWatch Form: X
Progress Notes: X
Other: X

SmartPA Clinical Proposal Form
© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.
Other company trademarks are also acknowledged.
Disposition of Edit

Denial: Exception code “0682” (Clinical Edit)
Rule Type: CE

Default Approval Period

6 months

References